NeuroVoices

At the 2023 AHS Annual Meeting, the chief of headache at UT Austin Dell Children’s Hospital discussed her presentation on a new educational intervention to improve knowledge of pediatric headache.

The professor of neurology at UMass Chan School of Medicine provided perspective on the benefits of pushing back school start times based on what research has shown.

The chief medical officer of Harmony Biosciences provided perspective on a proof-of-concept study assessing pitolisant’s (Wakix) clinical benefit in reducing excessive daytime sleepiness individuals with Prader-Willi syndrome.

Cornelia Drees, MD, senior associate consultant, Department of Neurology, Mayo Clinic, discussed the potential of microburst vagus nerve stimulation as a more targeted treatment for drug-resistant epilepsy.

The senior associate consultant in the Department of Neurology at Mayo Clinic provided insight on an early feasibility study on the clinical impact of microburst vagus nerve stimulation in patients with drug-resistant epilepsy.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

The chief scientific officer at Alzheon discussed new, positive 12-month findings on ALZ-801, an investigational agent in development for patients with early-stage Alzheimer disease.

The president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.

The chair of the Department of Neurology at Cedars Sinai Medical Center provided perspective on National MS Education and Awareness Month, and the changes to MS education in recent years.

The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided insight on new considerations for interpreting data from cognitive and functional measures in trials assessing agents for Alzheimer disease.

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

The executive direct of Cure CMD discussed the state of care for patients with congenital muscular dystrophies, the need for new treatments, and the patience with gene therapies.

The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center provided insight on the promising future of treating radiologically isolated syndrome at its earliest stages.

The executive director of Cure CMD provided perspective on a new 10-month program that aims to align patient and clinician perspectives on certain rare neuromuscular disorders.

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

The director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.

The executive director of Banner Alzheimer’s Institute discussed the efforts being done within the field to improve prevention and therapeutics for Alzheimer disease.

The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on several analyses from the N-MOmentum trial that highlight the clinical use of biomarkers in NMO and NMOSD.

The adult neurologist at Allegheny Health Network provided perspective on why there’s never been a better time to treat patients with myasthenia gravis.

The neurologist at Allegheny Health Network’s Neuroscience Institute provided perspective on a new phase 3 trial assessing fenebrutinib, an investigational BTK inhibitor for relapsing multiple sclerosis.

The adult neurologist at Allegheny Health Network discussed the ever-changing landscape of therapies for myasthenia gravis and shift toward more holistic disease management.